Amount Raised
$46 Million
Round Type
Funding Round
San DiegoBiotechnologyHealthcareHealth CareTherapeuticsInvestors
Description
ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company’s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital all participating in the financing. In conjunction with this financing, Dr. Lorence Kim of Ascenta Capital has joined the Company’s Board of Directors.
Quick answer
ADARx Pharmaceuticals, Inc. raised $46 Million in a Funding Round round, dated January 20, 2023. Investors: Sirona Capital, Lilly Asia Ventures, SR One Capital Management, Orbi Med Advisors and Ascenta Capital. ADARx Pharmaceuticals, Inc. is based in San Diego, California, United States.
- How much did ADARx Pharmaceuticals, Inc. raise?
- ADARx Pharmaceuticals, Inc. raised $46 Million in a Funding Round round on January 20, 2023.
- Who invested in ADARx Pharmaceuticals, Inc?
- Sirona Capital, Lilly Asia Ventures, SR One Capital Management, Orbi Med Advisors and Ascenta Capital are named as investors in this round.
- What does ADARx Pharmaceuticals, Inc. do?
- ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts.
- Where is ADARx Pharmaceuticals, Inc. based and how big is it?
- ADARx Pharmaceuticals, Inc. is based in San Diego, California, United States. Fundz records about 103 employees.
- Who are the decision-makers at ADARx Pharmaceuticals, Inc?
- Fundz holds 1 contact at ADARx Pharmaceuticals, Inc., including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as ADARx Pharmaceuticals, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Tessera Defense & Homeland Security Inc. raised $1.5M (Seed) on February 27, 2023.
- Azora Therapeutics, Inc. (DE) raised $62K (Pre-Seed) on February 23, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- QurAlis raised $60M on December 20, 2022.
- NewcelX raised $10M on December 13, 2022.
Who to call at ADARx Pharmaceuticals, Inc., and when
A new round usually means ADARx Pharmaceuticals, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ADARx Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ADARx Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ADARx Pharmaceuticals, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ADARx Pharmaceuticals, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
ADARx Pharmaceuticals, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.